Antonino Biroccio, born in Reggio Calabria, graduated in Pharmaceutical Chemistry with a doctorate in Genetics and Molecular Biology. And he took on the role of General Manager of GSK Italia as well as being President and CEO of GSK SpA.
“The primary objective of my mandate will be to contribute to promoting innovation, the real one which, once introduced, improves health and living conditions, economic prosperity, generating attractiveness and competitiveness, with an eye on the short coverage of costs, in particular healthcare costs put severely under pressure by a progressively aging population, with greater health needs”
says Biroccio.
GSK has been present in Italy since the beginning of the twentieth century and has always continued to grow as a full-cycle multinational, with two research centers and two production plants, 4200 employees, 1.6 billion euros in turnover, a third of which is exported to over 100 countries around the world. Investments in the country, equal to 324 million, represent 20 percent of the turnover and 8 percent of the total investments in research and production of all the pharmaceutical companies present in Italy.
